Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 3
2021 6
2022 3
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
Provencio M, Ortega AL, Coves-Sarto J, Calvo V, Marsé-Fabregat R, Dómine M, Guirado M, Carcereny E, Fernández N, Álvarez R, Blanco R, León-Mateos L, Sánchez-Torres JM, Sullivan IG, Cobo M, Sánchez-Hernández A, Massuti B, Sierra-Rodero B, Mártinez-Toledo C, Serna-Blasco R, Romero A, Cruz-Bermúdez A. Provencio M, et al. Among authors: ortega al. JAMA Oncol. 2023 Mar 1;9(3):344-353. doi: 10.1001/jamaoncol.2022.5959. JAMA Oncol. 2023. PMID: 36520426 Free PMC article.
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
Postel-Vinay S, Coves J, Texier M, Aldea M, Gazzah A, Dómine M, Planchard D, De Las Peñas R, Sala Gonzalez MA, Viteri S, Perez J, Ortega AL, Moran T, Camps C, Lopez-Martin A, Provencio M, Soria JC, Besse B, Massuti B, Rosell R. Postel-Vinay S, et al. Among authors: ortega al. Br J Cancer. 2024 Feb;130(3):417-424. doi: 10.1038/s41416-023-02514-5. Epub 2023 Dec 14. Br J Cancer. 2024. PMID: 38097741 Clinical Trial.
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.
Romero A, Jantus-Lewintre E, García-Peláez B, Royuela A, Insa A, Cruz P, Collazo A, Pérez Altozano J, Vidal OJ, Diz P, Cobo M, Hernández B, Vázquez Estevez S, Benítez G, Guirado M, Majem M, Bernabé R, Ortega AL, Blasco A, Bosch-Barrera J, Jurado JM, García González J, Viteri S, Garcia Giron C, Massutí B, Lopez Martín A, Rodriguez-Festa A, Calabuig-Fariñas S, Molina-Vila MÁ, Provencio M. Romero A, et al. Among authors: ortega al. Mol Oncol. 2021 Jan;15(1):43-56. doi: 10.1002/1878-0261.12832. Epub 2020 Nov 13. Mol Oncol. 2021. PMID: 33107189 Free PMC article.
[Representativeness of the Spanish Thoracic Tumour Registry. Comparison of sociodemographic data with other national registries].
Candal-Pedreira C, Ruano-Ravina A, Carcereny E, Rodríguez-Abreu D, Guirado-Risueño M, López-Castro R, Massutí B, Blasco A, Ortega AL, Provencio M. Candal-Pedreira C, et al. Among authors: ortega al. Gac Sanit. 2022 Nov-Dec;36(6):540-545. doi: 10.1016/j.gaceta.2022.02.013. Epub 2022 May 27. Gac Sanit. 2022. PMID: 35637054 Free article. Spanish.
Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain.
Majem M, Álvarez R, Ortega AL, Ruiz de Alda L, Gordo R, García JF, Ivanova-Markova Y, González-Domínguez A, San Cristóbal RS, Rojo F. Majem M, et al. Among authors: ortega al. Glob Reg Health Technol Assess. 2022 Sep 12;9:82-90. doi: 10.33393/grhta.2022.2449. eCollection 2022 Jan-Dec. Glob Reg Health Technol Assess. 2022. PMID: 36628311 Free PMC article.
Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.
Ruano-Ravina A, Provencio M, Calvo de Juan V, Carcereny E, Estival A, Rodríguez-Abreu D, Benítez G, López-Castro R, Belver M, Guirado-Risueño M, Guirao-Rubio C, Blasco A, Massutí B, Ortega AL, Cobo M, Mosquera-Martínez J, Aguado de la Rosa C, Bosch-Barrera J, Sánchez-Gastaldo A, Del Barco Morillo E, Juan Ó, Dómine M, Trigo JM, Pereiro Corbacho D, Oramas J. Ruano-Ravina A, et al. Among authors: ortega al. Transl Lung Cancer Res. 2021 Oct;10(10):3902-3911. doi: 10.21037/tlcr-21-559. Transl Lung Cancer Res. 2021. PMID: 34858780 Free PMC article.
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
Provencio M, Cobo M, Rodriguez-Abreu D, Calvo V, Carcereny E, Cantero A, Bernabé R, Benitez G, Castro RL, Massutí B, Del Barco E, García Campelo R, Guirado M, Camps C, Ortega AL, González Larriba JL, Sánchez A, Casal J, Sala MA, Juan-Vidal O, Bosch-Barrera J, Oramas J, Dómine M, Trigo JM, Blanco R, Calzas J, Morilla I, Padilla A, Pimentao J, Sousa PA, Torrente M. Provencio M, et al. Among authors: ortega al. BMC Cancer. 2022 Jul 5;22(1):732. doi: 10.1186/s12885-022-09830-8. BMC Cancer. 2022. PMID: 35790916 Free PMC article.
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection.
Provencio M, Majem M, Guirado M, Massuti B, de Las Peñas R, Ortega AL, Dómine M, Marsé R, Sala MÁ, Paredes A, Morán T, Vázquez S, Coves J, Larriba JLG, Sánchez JM, Vicente D, Farré N, Fornos LF, Zapata I, Franco F, Serna-Blasco R, Romero A, Isla D. Provencio M, et al. Among authors: ortega al. Lung Cancer. 2021 Mar;153:25-34. doi: 10.1016/j.lungcan.2021.01.005. Epub 2021 Jan 10. Lung Cancer. 2021. PMID: 33453470 Clinical Trial.
19 results